India’s pharmaceuticals and medical devices sector has seen a FDI inflow to the tune of 11,888 crore rupees from April to December in the financial year ended on March 31, 2025. Apart from this, 13 FDI proposals worth 7,246.40 crore rupees for brownfield projects during 2024-25 have been approved, taking the total FDI to 19,134.4 crore rupees, according to figures compiled by the Department of Pharmaceuticals.
According to an official statement, the government’s Production Linked Incentive (PLI) Scheme has turned out to be a transformative initiative for boosting domestic manufacturing, attracting investments, reducing reliance on imports and increasing exports. One of the significant achievements under the PLI scheme has been the surpassing of targeted investments. While the initial commitment was 3,938.57 crore rupees, the actual realised investment has already reached 4,253.92 crore rupees as of December 2024.
Under the PLI scheme for Bulk Drugs, a total of 48 projects have been selected under the scheme, of which 34 projects have been commissioned for 25 bulk drugs as of December 2024.